U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Pancreatic Neuroendocrine Carcinoma

MedGen UID:
1669537
•Concept ID:
C4727010
•
Neoplastic Process

Definition

Pancreatic neuroendocrine carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Pancreatic Neuroendocrine Carcinoma

Professional guidelines

PubMed

Radiotherapy in the management of rare gastrointestinal cancers: A systematic review.
Bellefkih FZ, Benchakroun N, Lalya I, Amaoui B, El Kacemi H, Acharki A, El Hfid M, El Mazghi A, Chekrine T, Bouchbika Z, Jouhadi H, Sahraoui S, Tawfiq N, Michalet M
Cancer Radiother 2023 Sep;27(6-7):622-637. Epub 2023 Jul 25 doi: 10.1016/j.canrad.2023.06.010. PMID: 37500390
Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
Chatani PD, Agarwal SK, Sadowski SM
Front Endocrinol (Lausanne) 2020;11:575620. Epub 2021 Jan 18 doi: 10.3389/fendo.2020.575620. PMID: 33537001Free PMC Article
Pancreatic neuroendocrine tumors: Nosography, management and treatment.
Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F
Int J Surg 2016 Apr;28 Suppl 1:S156-62. Epub 2015 Dec 18 doi: 10.1016/j.ijsu.2015.12.052. PMID: 26708853

Recent clinical studies

Etiology

A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T, Furuse J
Neuroendocrinology 2020;110(11-12):988-993. Epub 2020 Jan 2 doi: 10.1159/000505550. PMID: 31986515
The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature.
Montanier N, Joubert-Zakeyh J, Pétorin C, Montoriol PF, Maqdasy S, Kelly A
Medicine (Baltimore) 2017 Feb;96(6):e6062. doi: 10.1097/MD.0000000000006062. PMID: 28178157Free PMC Article

Diagnosis

The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature.
Montanier N, Joubert-Zakeyh J, Pétorin C, Montoriol PF, Maqdasy S, Kelly A
Medicine (Baltimore) 2017 Feb;96(6):e6062. doi: 10.1097/MD.0000000000006062. PMID: 28178157Free PMC Article

Therapy

A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T, Furuse J
Neuroendocrinology 2020;110(11-12):988-993. Epub 2020 Jan 2 doi: 10.1159/000505550. PMID: 31986515
The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature.
Montanier N, Joubert-Zakeyh J, Pétorin C, Montoriol PF, Maqdasy S, Kelly A
Medicine (Baltimore) 2017 Feb;96(6):e6062. doi: 10.1097/MD.0000000000006062. PMID: 28178157Free PMC Article

Prognosis

The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature.
Montanier N, Joubert-Zakeyh J, Pétorin C, Montoriol PF, Maqdasy S, Kelly A
Medicine (Baltimore) 2017 Feb;96(6):e6062. doi: 10.1097/MD.0000000000006062. PMID: 28178157Free PMC Article

Clinical prediction guides

A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
Okuyama H, Ikeda M, Okusaka T, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T, Furuse J
Neuroendocrinology 2020;110(11-12):988-993. Epub 2020 Jan 2 doi: 10.1159/000505550. PMID: 31986515

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...